Sarepta Therapeutics (SRPT) Stocks Latest Headlines

quotes
- Overview
- Performance Report
charts
- Interactive Chart
- Technical Chart
technicals
options
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (BATS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Latest Headlines for [[ item.sessionDateDisplayLong ]]

Alerts

Watch

Help

Options Traders Expect Huge Moves in Sarepta (SRPT) Stock Zacks Equity Research - Zacks Investment Research - Fri Jun 15, 7:51AM CDT

Zacks Equity Research - ZACKS - Fri Jun 15, 7:51AM CDT

Sarepta (SRPT) needs investors to pay close attention to the stock based on moves in the options market lately.

Sarepta Inks Manufacturing Deal for Gene Therapy Program Zacks Equity Research - Zacks Investment Research - Thu Jun 14, 8:45AM CDT

Zacks Equity Research - ZACKS - Thu Jun 14, 8:45AM CDT

Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.

Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply GlobeNewswire - Wed Jun 13, 7:30AM CDT

CMTX - Wed Jun 13, 7:30AM CDT

-- The partnership will provide commercial supply for a potential micro-dystrophin gene therapy product launch and other neuromuscular programs in the pipeline --

Sarepta Therapeu Shares Up 24.3% Since SmarTrend's Buy Recommendation (SRPT) Comtex SmarTrend(R) - Wed Jun 13, 12:29AM CDT

CMTX - Wed Jun 13, 12:29AM CDT

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on April 11th, 2018 at $79.45. In approximately 2 months, Sarepta Therapeu has returned 24.31% as of today's recent price of $98.76.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Jun 11, 5:10PM CDT

CMTX - Mon Jun 11, 5:10PM CDT

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted...

Sarepta Therapeutics to Host R&D Day on Tuesday, June 19, 2018 GlobeNewswire - Fri Jun 8, 7:30AM CDT

CMTX - Fri Jun 8, 7:30AM CDT

-- Event to be Webcast Live -

Sarepta Therapeutics Appoints Gilmore O'Neill, M.B., M.M.Sc. as Chief Medical Officer GlobeNewswire - Thu Jun 7, 7:30AM CDT

CMTX - Thu Jun 7, 7:30AM CDT

Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO Zacks Equity Research - Zacks Investment Research - Wed Jun 6, 7:31AM CDT

Zacks Equity Research - ZACKS - Wed Jun 6, 7:31AM CDT

The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

Sarepta Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire - Tue Jun 5, 7:30AM CDT

CMTX - Tue Jun 5, 7:30AM CDT

Wired News - CHMP Adopted Negative Opinion for Sarepta's EXONDYS in Europe to Treat Patients with Duchenne Muscular Dystrophy ACCESSWIRE - Tue Jun 5, 6:28AM CDT

CMTX - Tue Jun 5, 6:28AM CDT

Stock Monitor: Versartis Post Earnings Reporting

Watch for Sarepta Therapeu to Potentially Pullback After Gaining 1.98% Yesterday Comtex SmarTrend(R) - Mon Jun 4, 12:49PM CDT

CMTX - Mon Jun 4, 12:49PM CDT

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $95.21 to a high of $97.94. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high...

Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit GlobeNewswire - Mon Jun 4, 7:30AM CDT

CMTX - Mon Jun 4, 7:30AM CDT

-- Dr. Rodino-Klapac, a National Institutes of Health Fellow, is a pioneer in the advancement of gene therapy to treat human disease, whose discoveries have advanced six gene therapy programs from bench...

As Anticipated, Sarepta Receives Negative CHMP Opinion for EXONDYS(R) (eteplirsen) to Treat Patients with Duchenne Muscular Dystrophy in Europe GlobeNewswire - Fri Jun 1, 6:00AM CDT

CMTX - Fri Jun 1, 6:00AM CDT

-- Sarepta will seek re-examination of the opinion and request that a Scientific Advisory Group (SAG) be convened --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu May 31, 5:00PM CDT

CMTX - Thu May 31, 5:00PM CDT

Here's Why Sarepta is Up More Than 60% So Far This Year Zacks Equity Research - Zacks Investment Research - Tue May 29, 9:09AM CDT

Zacks Equity Research - ZACKS - Tue May 29, 9:09AM CDT

Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.

16.6% Return Seen to Date on SmarTrend Sarepta Therapeu Call (SRPT) Comtex SmarTrend(R) - Wed May 16, 4:59AM CDT

CMTX - Wed May 16, 4:59AM CDT

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on April 11th, 2018 at $79.45. In approximately 1 month, Sarepta Therapeu has returned 16.65% as of today's recent price of $92.67.

Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Alnylam Pharmaceuticals ACCESSWIRE - Mon May 7, 7:20AM CDT

CMTX - Mon May 7, 7:20AM CDT

NEW YORK, NY / ACCESSWIRE / May 7, 2018 / U.S. markets rallied on Friday, despite trade uncertainties and weak employment data, as a surge in Apple led to strong gains by the tech sector. The Dow Jones...

Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy PR Newswire - Mon May 7, 6:30AM CDT

CMTX - Mon May 7, 6:30AM CDT

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the expansion of its partnership with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) to assist clinicians in...

SmarTrend Watching for Potential Pullback in Shares of Sarepta Therapeu After 12.10% Gain Comtex SmarTrend(R) - Fri May 4, 11:53AM CDT

CMTX - Fri May 4, 11:53AM CDT

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $76.20 to a high of $89.19. Yesterday, the shares gained 12.1%, which took the trading range above the 3-day high...

Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress Zacks Equity Research - Zacks Investment Research - Fri May 4, 10:24AM CDT

Zacks Equity Research - ZACKS - Fri May 4, 10:24AM CDT

Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.

Agricharts Market Commentary

Corn futures closed with most nearby contracts 1 to 2 cents lower on Friday, despite showing gains at midday. Front month July lost 4.37% on the week. December fell to within 1 1/4 cents of the life of contract low in the overnight session. Managed m...
Read More

Fri Jun 15, 4:53PM CDT

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Financial Technology & Market Data

quotes

charts

technicals

options

company

analysts

financials